Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Phloroglucinol→

Phloroglucinol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
108-73-6
Molecular formula
C6H6O3
Molecular weight
126.11 g/mol
Drug class
Non-anticholinergic smooth-muscle antispasmodic
Mechanism of action
Relaxes smooth muscle and reduces spasm. A proposed mechanism includes inhibition of catechol-O-methyltransferase (COMT)-related signalling and modulation of calcium-dependent contractile activity; the clinical mechanism is not completely established.
Indications / reported uses
  • Symptomatic relief of painful smooth-muscle spasm of the gastrointestinal, biliary and urinary tracts where phloroglucinol-containing products are authorised.

Sources: https://www.ema.europa.eu/en/documents/mrl-report/phloroglucinol-trimethylphloroglucinol-summary-report-committee-veterinary-medicinal-products_en.pdf · https://pubmed.ncbi.nlm.nih.gov/?term=phloroglucinol+antispasmodic+clinical · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Phloroglucinol Environmental Risk Assessment (ERA) (the Phloroglucinol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.